openPR Logo
Press release

Synovial Sarcoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, ROA, and Companies by DelveInsight | CFT 8634, FHD 609, BA-3011, more

05-24-2024 02:11 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Synovial Sarcoma Pipeline

Synovial Sarcoma Pipeline

(Albany, USA) As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Synovial Sarcoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Synovial Sarcoma Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Synovial Sarcoma Therapeutics Market.
The Synovial Sarcoma pipeline report provides a detailed description of the Synovial Sarcoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Synovial Sarcoma Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Synovial Sarcoma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Synovial Sarcoma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Synovial Sarcoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Synovial Sarcoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Synovial Sarcoma Therapeutics Domain @
https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Synovial Sarcoma Therapeutics Analysis
There are approx. 14+ key companies developing therapies for Synovial-Sarcoma. Currently, BioAtla is leading the therapeutics market with its Synovial-Sarcoma drug candidates in the most advanced stage of clinical development.

Synovial Sarcoma Companies in the Therapeutics Market Include:
• BioAtla
• C4 Therapeutics
• Foghorn Therapeutics
• OncoTherapy Science
• Adaptimmune
• Incyte Corporation
• PharmaMar
And Many Others

Emerging and Marketed Synovial Sarcoma Therapies Covered in the Report Include:
• CFT 8634: C4 Therapeutics
• FHD 609: Foghorn Therapeutics
• BA-3011: BioAtla
And Many More

Get an in-depth Assessment of the Emerging Therapies and Synovial Sarcoma Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Report Covers the Emerging Synovial Sarcoma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Synovial-Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Synovial Sarcoma Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. Synovial Sarcoma Current Treatment Patterns
4. Synovial Sarcoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Synovial Sarcoma Late-Stage Products (Phase-III)
7. Synovial Sarcoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Synovial Sarcoma Discontinued Products
13. Synovial Sarcoma Product Profiles
14. Synovial Sarcoma Companies
15. Synovial Sarcoma Drugs
16. Dormant and Discontinued Products
17. Synovial Sarcoma Unmet Needs
18. Synovial Sarcoma Future Perspectives
19. Synovial Sarcoma Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Synovial Sarcoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, ROA, and Companies by DelveInsight | CFT 8634, FHD 609, BA-3011, more here

News-ID: 3511823 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Synovial

Synovial Sarcoma Market Projected to Reach USD 420 Million by 2034
Synovial sarcoma (SS) is a rare and aggressive form of soft tissue sarcoma, most commonly affecting adolescents and young adults. Though it accounts for only 5-10% of all soft tissue sarcomas, its rarity and severity make it a significant focus of rare cancer research. The disease is characterized by its chromosomal translocation (t(X;18)) and its tendency to metastasize, primarily to the lungs, creating challenges in long-term patient survival. Download Full PDF
Synovial Sarcoma Market Clinical Advancements and Commercial Forecast
Synovial sarcoma is a rare, aggressive soft tissue cancer that typically arises near the joints of the arm or leg but can occur in other parts of the body. Although it accounts for less than 10% of all soft tissue sarcomas, synovial sarcoma often affects young adults and adolescents, making it a critical area of oncology research. Due to limited treatment options and poor survival outcomes, there has been an
Synovial Sarcoma Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Synovial Sarcoma Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Synovial
Synovial Sarcoma Market Size, Trends, Industry Value and Latest Insights Till 20 …
What is the market size of synovial sarcoma? The synovial sarcoma market reached a value of US$ 75.3 Million in 2023 and expected  to reach US$ 114.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034. Request for a Sample of this Report: https://www.imarcgroup.com/synovial-sarcoma-market/requestsample Synovial Sarcoma Market Trends: Synovial sarcoma is a rare and aggressive form of soft tissue cancer that primarily affects young adults. Despite its rarity, the market for
Synovial Sarcoma Market Analysis: Growth, Trends, and Key Players
The Synovial Sarcoma Market is set for substantial expansion, with an anticipated Compound Annual Growth Rate (CAGR) of 4% during the forecast period spanning from 2024 to 2032. This growth can be attributed to various factors such as the increasing incidence of synovial sarcoma, advancements in medical technology, and the development of targeted therapies. In this comprehensive blog post, we will provide an in-depth overview of the Synovial Sarcoma Market,
Synovial Sarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Synovial Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Synovial Sarcoma market size